成都圣诺生物科技股份有限公司部分董事、高级管理人员减持股份计划公告

Core Viewpoint - The announcement details a share reduction plan by certain directors and senior management of Chengdu Saintno Biotechnology Co., Ltd. due to personal financial needs, with specific share quantities and timelines outlined for the planned reductions [3][11]. Summary by Sections Shareholding Information - As of the announcement date, Vice General Manager Ma Zhonggang holds 175,616 shares, accounting for 0.1116% of the total share capital, with 156,800 shares held indirectly through an employee stock ownership platform [2]. - Director and Financial Officer Wu Li holds 116,816 shares, representing 0.0742% of the total share capital, with 98,000 shares held indirectly through the same platform [2]. Reduction Plan Details - Ma Zhonggang and Wu Li plan to reduce their holdings by up to 18,816 shares each, which is 0.0120% of the total share capital, within three months after the announcement date [3][6]. - The reduction will occur through centralized bidding or block trading, and the number of shares may be adjusted in case of corporate actions like dividends or stock splits [3][11]. Background of Reducing Parties - The shares intended for reduction originate from stock incentive plans, and the reducing parties do not have any concerted actions with other shareholders [4][5]. Compliance and Commitments - The reducing parties have previously committed to not transferring their shares for a specified period post-IPO, with conditions for extending the lock-up period if certain stock price conditions are met [7][9]. - They are also bound by regulations that limit the amount of shares they can transfer annually and restrict transfers for six months post-employment [8][10].